Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive T-cell lymphoma. A 63-year-old man was diagnosed with AITL. He received 6 cycles of CHOP therapy, but showed progressive disease. Subsequently, he received ESHAP chemotherapy; however, it was not effective. He received mogamulizumab (an anti-CCR4 monoclonal antibody). After 4 cycles, his respiratory condition worsened and he was diagnosed with cytomegalovirus (CMV) pneumonia. Despite antiviral and antibiotic therapy, he died. We speculate that the combination of progressive lymphoma with mogamulizumab and chemotherapy likely caused CMV pneumonia. Because mogamulizumab therapy causes immunosuppression, if CMV pneumonia is suspected, then rapid treatment should be initiated.
Introduction
Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive T-cell lymphoma, classified as a peripheral T-cell lymphoma (PTCL) according to the World Health Organization classification criteria (1) . The prognosis for AITL is poor (2); cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) chemotherapy is often used as the first-line therapy for patients with AITL; however, the treatment outcomes have been reported to be limited (3) .
Mogamulizumab is a defucosylated anti-CC-chemokine receptor 4 (CCR4) monoclonal antibody used for the treatment of adult T-cell leukemia/lymphoma, that has recently shown improved treatment outcomes (4). Of note, CCR4, which is expressed by most adult T-cell leukemia/lymphoma cells, including PTCLs, and is known to be a marker for type 2 helper or regulatory T (Treg) cells, is associated with a particularly poor prognosis (5, 6) . Recently, Ogura et al. reported the effectiveness of mogamulizumab for patients with relapsed PTCL and cutaneous T-cell lymphoma with an acceptable toxicity (7) . In a previous study, the overall response rate to mogamulizumab was 50% for patients with AITL, with the most common adverse events being infusion reaction and skin rash (4) . Mogamulizumab is a new monoclonal antibody, and thus, adverse events regarding infection remain largely unknown. We herein experienced an AITL patient suffering from cytomegalovirus (CMV) pneumonia after mogamulizumab therapy. limbs, and skin rash. A positron emission tomography/computed tomography (CT) scan revealed no accumulation of 18F-fluorodeoxyglucose, and he was thus judged as having a complete response (CR). However, pancytopenia appeared in addition to the clinical symptoms. Subsequently, he underwent an additional bone marrow biopsy, upon which lymphoma infiltration was detected, and he was diagnosed with progressive disease. His Eastern Cooperative Oncology Group performance status was 3. He received etoposide, carboplatin, cytarabine, methylprednisolone (ESHAP) chemotherapy, however this was ineffective. As a result, he received an intravenous injection of 1.0 mg/kg mogamulizumab every week for 4 courses. After the termination of the 4 cycles of mogamulizumab, he underwent a bone marrow examination, which revealed lymphoma cell infiltration. Five days after the fourth mogamulizumab injection, his respiratory condition worsened. Chest CT revealed a ground-glass opacity, reticular pattern and bilateral pleural effusion (Figure) . Only normal flora was detected on a sputum specimen. Aspergillus antigenemia and β-D-glucan were negative. After CT and the sputum examination, CMV pneumonia was suspected; thus, ganciclovir (600 mg per day) and empiric antibiotic therapy (tazobactam/piperacillin, 13.5 g per day) were administered. The detection of blood CMV pp65 antigens (C10/11) was performed using immunofluorescence, which revealed 1411/1268 positive CMV-infected cells per slide. Despite the antiviral and antibiotic therapy, his respiratory status did not improve, and the patient died 5 days from the development of the respiratory changes.
Discussion
CMV infection typically occurs in immunocompromised hosts such as patients with acquired immunodeficiency syndrome, undergoing organ or stem cell transplantation, or with hematological malignancies.
Recently, several monoclonal antibodies, such as alemtuzumab (anti-CD52) and rituximab (anti-CD20), have been associated with the development of CMV infection (8, 9) . Rituximab decreases the number of normal CD20-positive cells (9) , while alemtuzumab causes lymphocytotoxic immunosuppression through the suppression of T-cell function and decrease in the number of CD4 cells (10). Ohyama et al. described that 2 of 4 patients with ATLL who underwent mogamulizumab therapy developed CMV infection (11) . Two patients with CMV infection achieved molecular CR. One patient died because of CMV encephalitis. Furthermore, Ishida et al. reported that 4 patients (14%) who received mLSG15 combined with mogamulizumab developed CMV infection, which was not observed in the patients who received mLSG15 therapy alone (12) . This report suggested that the addition of mogamulizumab to systemic therapy might further increase the incidence of CMV infection. CCR4 is not only expressed on tumor cells, but also on Treg cells (11); hence, the decrease in the number of Treg cells is expected to be involved in the development of immune disorders. Chemaly et al. reported that, out of 3091 patients with lymphoma, 31 patients experienced CMV pneumonia (13) , whereas in the report by Tay et al., of 534 patients with lymphoma, 48 patients experienced CMV infection, and 4 patients were diagnosed with CMV pneumonia (14) . CMV infection is believed to develop as a result of intensive immunochemotherapy and monoclonal antibody treatment in patients with lymphoma.
CMV pneumonia is defined by the detection of CMV in the bronchoalveolar lavage fluid or lung tissue samples, combined with the clinical symptoms. However, as our patient's general condition was very poor, bronchoscopy could not be performed. Furthermore, in the sputum specimen, only normal flora was detected, and β-D-glucan and Aspergillus antigenemia were negative. CMV pneumonia typically presents as general findings, such as ground-glass opacities and patchy consolidation on CT. Therefore, CMV pneumonia is typically diagnosed according to CMV antigenemia, a CT scan and other examinations, such as those mentioned above. However, Chemaly et al. described that 53% of lymphoma patients with CMV pneumonia had coinfections (13). Our patient was a severely immunocompromised host, thus he may have had underdetermined coinfections. Chang et al. suggested that CMV antigenemia was not sensitive for patients with CMV pneumonia (15) . Indeed, if possible, bronchoscopy should be performed when CMV pneumonia is suspected.
Lastly, Tay et al. reported that out of a total 534 lymphoma patients, all 12 patients with CMV infection or endorgan disease who died had progressive disease (14) . Similarly, in our case, it is possible that CMV pneumonia may also be associated with refractory lymphoma.
In conclusion, the present case demonstrated that the combination of the progressive status of lymphoma with the use of mogamulizumab and intensive chemotherapy likely resulted in CMV pneumonia. Mogamulizumab is known to cause immunosuppression, and thus, if CMV pneumonia is suspected, then rapid treatment with antibiotic therapy should be initiated. Furthermore, careful monitoring for CMV infection is recommended for patients receiving mogamulizumab combined with intensive chemotherapy.
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